^
    over3years
    Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. (PubMed, J Exp Clin Cancer Res)
    We then present our data to show the anticancer drug FL118 modulation of these protein targets and RCC cell/tumor growth. Finally, we include additional data to show a promising FL118 analogue (FL496) for treating the specialized type 2 papillary RCC.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MCL1 (Myeloid cell leukemia 1) • MDM2 (E3 ubiquitin protein ligase) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • MDM4 (The mouse double minute 4) • BIRC5 (Baculoviral IAP repeat containing 5) • EPAS1 (Endothelial PAS domain protein 1) • XIAP (X-Linked Inhibitor Of Apoptosis) • ERCC6 (Excision repair cross-complementation group 6)
    |
    KRAS mutation
    |
    FL118 • FL-496